Demeetra AgBio, Inc.
10:30 AM - 10:45 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 104A
Demeetra’s proprietary gene editing technologies are being applied to unique biomanufacturing strategies for therapeutics as well as industrial and agricultural products. Core technologies Cas-CLOVER nuclease and piggyBac transposase have been validated and are out-licensed for bioprocessing and agriculture. One of our internal R&D missions is the discovery and bioprocessing of cannabinoid derivatives for the treatment of chronic inflammation and other diseases.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
KY
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
DM300 and DM350-p novel cannabinoid derivatives for the treatment of Crohn's
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
